The Food and Drug Administration said Thursday that the longstanding shortage of Eli Lilly’s weight-loss drug Zepbound and its Type 2 diabetes medicine Mounjaro is officially over.The determination will have a sweeping impact on the sometimes murky industry of telehealth websites and compounding pharmacies selling legal knockoff GLP-1 weight-loss medicines that have exploded over the past year.

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline access to the popular treatment.